AU2002230935A1 - Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation - Google Patents

Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation

Info

Publication number
AU2002230935A1
AU2002230935A1 AU2002230935A AU3093502A AU2002230935A1 AU 2002230935 A1 AU2002230935 A1 AU 2002230935A1 AU 2002230935 A AU2002230935 A AU 2002230935A AU 3093502 A AU3093502 A AU 3093502A AU 2002230935 A1 AU2002230935 A1 AU 2002230935A1
Authority
AU
Australia
Prior art keywords
ondansetron hydrochloride
ondansetron
hydrochloride form
ethanol
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002230935A
Other languages
English (en)
Inventor
Judith Aronhime
Ramy Lidor-Hadas
Revital Lifshitz
Asher Maymon
Valerie Niddam
Shlomit Weizel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of AU2002230935A1 publication Critical patent/AU2002230935A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Steroid Compounds (AREA)
AU2002230935A 2000-10-30 2001-10-30 Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation Abandoned AU2002230935A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US24428300P 2000-10-30 2000-10-30
US60/244,283 2000-10-30
US25381900P 2000-11-29 2000-11-29
US60/253,819 2000-11-29
US26553901P 2001-01-31 2001-01-31
US60/265,539 2001-01-31
PCT/US2001/048720 WO2002036558A2 (en) 2000-10-30 2001-10-30 Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation

Publications (1)

Publication Number Publication Date
AU2002230935A1 true AU2002230935A1 (en) 2002-05-15

Family

ID=27399743

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002230935A Abandoned AU2002230935A1 (en) 2000-10-30 2001-10-30 Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation

Country Status (20)

Country Link
US (1) US20020107275A1 (de)
EP (1) EP1339707A2 (de)
JP (1) JP2004525083A (de)
KR (1) KR20030042038A (de)
CN (1) CN1498216A (de)
AU (1) AU2002230935A1 (de)
CA (1) CA2426026A1 (de)
CZ (1) CZ20031397A3 (de)
DE (1) DE01991193T1 (de)
ES (1) ES2204358T1 (de)
HR (1) HRP20030432A2 (de)
HU (1) HUP0401239A2 (de)
IL (1) IL155644A0 (de)
IS (1) IS6797A (de)
MX (1) MXPA03003761A (de)
NO (1) NO20031928L (de)
PL (1) PL366150A1 (de)
SK (1) SK6182003A3 (de)
WO (1) WO2002036558A2 (de)
YU (1) YU32003A (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070054749A (ko) * 2001-01-11 2007-05-29 테바 파마슈티컬 인더스트리즈 리미티드 순수한 온단세트론 하이드로클로라이드 이수화물의 개선된제조 방법
EP1499623B1 (de) 2002-04-29 2007-06-13 TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Verfahren zur herstellung von 1,2,3,9-tetrahydro-9-methyl-3-¬(2-methyl-1h-imidazol-1-yl)methyl|-4h-carbazol-4-on
FI6164U1 (fi) * 2003-01-09 2004-03-15 Synthon Bv Ondansetronmuotoja
WO2006046253A1 (en) * 2004-10-26 2006-05-04 Ipca Laboratories Limited A one-pot process for the preparation of antiemetic agent, 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl)-1h-imidazole-1-yl)methyl]-4h-carbazol-4-o
BRPI0707324A2 (pt) * 2006-01-27 2011-05-03 Eurand Inc sistemas de fornecimento de fármaco compreendendo agente de bloqueio de serotonina 5-ht3 seletivo fracamente básico e ácidos orgánicos
NZ569984A (en) * 2006-01-27 2011-06-30 Eurand Inc Drug delivery systems comprising weakly basic drugs and organic acids
US20100105724A1 (en) * 2006-12-07 2010-04-29 Helsinn Healthcare Sa Crystalline and amorphous forms of palonosetron hydrochloride
US8133506B2 (en) 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
CN102190594A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀氯化氢水合物及其制备方法
CN102190595A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀溴化氢水合物及其制备方法
KR102495018B1 (ko) 2013-11-15 2023-02-06 아케비아 테라퓨틱스 인코포레이티드 ｛[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노｝아세트산의 고체형, 이의 조성물 및 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
DE201165T1 (de) * 1985-03-14 1989-04-20 Beecham Group P.L.C., Brentford, Gb Arzneimittel zur behandlung von emesis, anxietas und "irritable bowel syndrome".
GB8518741D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Process
GB8518742D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Process
GB8630071D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
GB8816187D0 (en) * 1988-07-07 1988-08-10 Glaxo Group Ltd Medicaments
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
EP1022025A3 (de) * 1991-06-26 2002-06-05 Sepracor, Inc. Verfahren und Zusammensetzungen zur Behandlung von Erbrechen, Übelkeit und anderen Störungen unter Verwendung von optisch reinem S(+)-ondansetron
CA2106642C (en) * 1992-10-14 2005-08-16 Peter Bod Carbazolone derivatives and process for preparing the same
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9423588D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
CN1045437C (zh) * 1994-12-29 1999-10-06 中国科学院上海有机化学研究所 恩丹西酮及其生理盐的合成
EP1207160A1 (de) * 2000-11-20 2002-05-22 Hanmi Pharm. Co., Ltd. Verfahren zur Herstellung von 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)-methyl)-4H-carbazol-4-one
EP1499623B1 (de) * 2002-04-29 2007-06-13 TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Verfahren zur herstellung von 1,2,3,9-tetrahydro-9-methyl-3-¬(2-methyl-1h-imidazol-1-yl)methyl|-4h-carbazol-4-on
JP2005529908A (ja) * 2002-04-30 2005-10-06 テバ ジョジセルジャール レースベニュタールシャシャーグ オンダンセトロンの新規結晶形、その製法、当該新規形を含有する医薬組成物、及び当該組成物を用いる吐気の治療方法

Also Published As

Publication number Publication date
HRP20030432A2 (en) 2004-06-30
MXPA03003761A (es) 2003-07-28
JP2004525083A (ja) 2004-08-19
DE01991193T1 (de) 2004-07-08
SK6182003A3 (en) 2004-03-02
NO20031928D0 (no) 2003-04-29
CN1498216A (zh) 2004-05-19
WO2002036558A2 (en) 2002-05-10
NO20031928L (no) 2003-06-27
YU32003A (sh) 2006-05-25
ES2204358T1 (es) 2004-05-01
HUP0401239A2 (hu) 2004-12-28
CA2426026A1 (en) 2002-05-10
EP1339707A2 (de) 2003-09-03
KR20030042038A (ko) 2003-05-27
PL366150A1 (en) 2005-01-24
IL155644A0 (en) 2003-11-23
US20020107275A1 (en) 2002-08-08
IS6797A (is) 2003-04-29
WO2002036558A3 (en) 2003-02-06
CZ20031397A3 (cs) 2003-11-12

Similar Documents

Publication Publication Date Title
US7332612B2 (en) Amorphous and crystalline forms of losartan potassium and process for their preparation
EP1511739B1 (de) Polymorphe formen von valsartan
US20040220210A1 (en) Zolpidem hemitartrate
EP2103612A1 (de) Kristalline Formen von Palonosetron-Hydrochlorid
EP1968978A2 (de) Formen von dolasetron-mesylat und verfahren zu ihrer herstellung
US20020107275A1 (en) Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation
WO2007109799A2 (en) Polymorphs of eszopiclone malate
EP2046777A2 (de) Amorphes eletriptan-hydrobromid sowie verfahren zur herstellung davon und anderer formen von eletriptan-hydrobromid
US20030004154A1 (en) New crystal forms of oxcarbazepine and processes for their preparation
WO2007128561A1 (en) Crystalline forms of letrozole and processes for making them
US7271269B2 (en) Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods
ZA200303000B (en) Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation.
US20060194833A1 (en) Crystalline 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses
WO2019211870A1 (en) Polymorphic forms of ibrutinib
EP1950204A1 (de) Amorphe Form von Valsartan
EP1795530A1 (de) Verfahren zur Herstellung von bekanntem Pantoprazolnatrium-sesquihydrat
US20060173068A1 (en) Amorphous and crystalline forms of dorzolamide hydrochloride and processes of making same
CN116239569A (zh) 一种半琥珀酸拉司米地坦晶型及其制备方法
ZA200403582B (en) Amorphous and crystalline forms of losartan potassium and process for their preparation.
EP2109613A2 (de) Polymorphe aus eszopiclon-malat

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application